M
Matthew E. Hart
Researcher at Oregon Health & Science University
Publications - 10
Citations - 1129
Matthew E. Hart is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Thyronamine & Vicinal. The author has an hindex of 6, co-authored 10 publications receiving 1093 citations. Previous affiliations of Matthew E. Hart include University of California, Irvine & Michigan State University.
Papers
More filters
Journal ArticleDOI
3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone.
Thomas S. Scanlan,Katherine L. Suchland,Matthew E. Hart,Grazia Chiellini,Yong Huang,Paul J. Kruzich,Sabina Frascarelli,Dane A. Crossley,James R. Bunzow,Simonetta Ronca-Testoni,Emil T. Lin,Daniel C. Hatton,Riccardo Zucchi,David K. Grandy +13 more
TL;DR: The discovery of 3-iodothyronamine (T1AM), a naturally occurring derivative of TH that in vitro is a potent agonist of the G protein–coupled trace amine receptor TAR1, suggests the existence of a new signaling pathway, stimulation of which leads to rapid physiological and behavioral consequences that are opposite those associated with excess TH.
Journal ArticleDOI
Increasing rates of reaction: microwave-assisted organic synthesis for combinatorial chemistry.
Journal ArticleDOI
Butane 2,3-Bisacetal Protection of Vicinal Diequatorial Diols.
Journal ArticleDOI
Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues.
Matthew E. Hart,Katherine L. Suchland,Motonori Miyakawa,James R. Bunzow,David K. Grandy,Thomas S. Scanlan +5 more
TL;DR: A large number of thyroamine derivatives were synthesized in an effort to understand the molecular basis of TAAR1 activation and hypothermia induction in mice, and compound 91 proved to be more potent than T(1)AM for TAAR2 activation and exhibits increased potency and efficacy for hypothermic induction.
Journal ArticleDOI
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
TL;DR: The ability of modified norcantharidin analogues to inhibit PP1 and PP2A correlates well with their observed anti-cancer activity against a panel of five cancer cell lines.